The following is a summary of “A Novel Macrophage-Activating Gel Improves Healing and Skin Quality After CO2 Laser Resurfacing of the Chest” published in the December 2022 issue of Dermatologic Surgery by Wu et al.
When healing from laser resurfacing, it’s crucial to stick to the recommended post-op care plan. However, there currently needs to be an agreement on which agents should be employed. To conduct a Phase 2B trial of a new macrophage-activating gel following fractionated ablative laser resurfacing of the chest to assess its safety and efficacy. A total of 42 adults who had fractionated CO2 laser resurfacing of the chest were randomly assigned to receive either an active treatment or a placebo for 5 days following surgery.
A blinded evaluator used the Fitzpatrick-Goldman Wrinkle Scale to evaluate the condition of the participants’ skin at both the pre-and post-study stages. In addition, the level of improvement and quality of the subjects’ skin was also evaluated, as was their level of satisfaction with the process. Within 28 days, 85% of active group individuals showed at least a 33% improvement compared to 50% of placebo group subjects (absolute difference 35%; P=.04).
At 28 days, 75% of participants in the active group had improved by at least 33% in elastosis, while only 35% of subjects in the placebo group had improved by at least 33% (a 40% absolute difference; P=.011). This study provides further evidence that the novel macrophage-activating gel significantly improves skin healing and quality following chest laser resurfacing.